Episode 44 - Myopia Is A Disease with Dr. Cary Herzberg

In this episode, the myopia management community is calling for the formal recognition of myopia as a chronic, progressive disease. The AAOMC (American Academy of Orthokeratology and Myopia Control) highlights a major regulatory gap in the U.S., where the FDA’s device division has approved multiple tools to slow myopia progression, but the drug division has yet to recognize or authorize pharmaceutical options such as SYD-101 low-dose atropine — despite growing global momentum and strong clinical evidence. With Europe and the U.K. moving ahead on atropine approvals, the Academy is urging policymakers, industry partners, and clinicians to align U.S. standards with the global scientific consensus. Their message is clear: early intervention works, low-dose atropine is safe and effective, and it belongs alongside optical and behavioral treatments in comprehensive myopia management. Dr. Cary Herzberg joins Matthew to share his perspective as a pioneer in myopia management — not only advocating for access and recognition, but working to amplify the collective voice of the profession. Together, they call on colleagues and the broader myopia-management community to join the AAOMC's efforts to elevate this message: Myopia Is a Disease. Find out more at aaomc.org Support the podcast at myopiamindset.com